Sign in
Taking people in United StatesPhase 3

Two Lower Olanzapine Doses to Prevent Nausea in Myeloma Patients

Compares two lower olanzapine doses to prevent nausea in people with multiple myeloma receiving melphalan.

Key facts

Who runs it
Augusta University
Where
Augusta, United StatesSee the site
Trial code
Registry title
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Status
Recruiting
Phase
Phase 3
People taking part
172 people, planned
Started
17 Sept 2024
Expected to end
Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Olanzapine
Record updated
22 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having an autologous stem cell transplant after high-dose melphalan chemotherapy. It compares two low doses of olanzapine to prevent nausea and vomiting.

Age
18 years or older
Sex
All sexes can join
Disease stage
Multiple myeloma; receiving high-dose melphalan 140-200 mg/m2 before an autologous stem cell transplant
Earlier treatment
No other antipsychotic medicine within 30 days before joining, or planned during the trial

Main reasons for not taking part

  • Allergy to olanzapine
  • Nausea or vomiting within 24 hours before joining
  • Other antipsychotic medicines such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone
  • Chronic alcoholism
  • Pregnant

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Receipt of high-dose melphalan 140-200 mg/m2
  • Autologous stem cell transplantation recipient

Who cannot take part

  • Documented nausea or vomiting within 24 hours prior to enrollment
  • Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy
  • Allergy to olanzapine
  • Chronic alcoholism
  • Pregnant
  • Decline or unable to provide informed consent

Where in United States

  • Wellstar MCGAugusta, United StatesContact: Amber Clemmons, PharmDTaking people

About the trial

What the trial wants to find out

Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.

The 2 groups in the trial

  • Olanzapine 2.5 mgTreatment being tested

    Olanzapine 2.5 mg dose to be given on the day of high-dose melphalan and three days after

    Treatment: Olanzapine

  • Olanzapine 5 mgExisting treatment, for comparison

    Olanzapine 5 mg dose to be given on the day of high-dose melphalan and three days after

    Treatment: Olanzapine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study
Plain-language title
Two Lower Olanzapine Doses to Prevent Nausea in Myeloma PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 November 2024